Something went wrong with the connection!

Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2030

 Breaking News
  • No posts were found

Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2030

April 30
11:12 2020
Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2030

DelveInsight has launched a new report on Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2030

DelveInsight’s Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Fibrodysplasia Ossificans Progressiva (FOP) , historical and forecasted epidemiology as well as the Fibrodysplasia Ossificans Progressiva (FOP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Fibrodysplasia Ossificans Progressiva (FOP) market report provides current treatment practices, emerging drugs, Fibrodysplasia Ossificans Progressiva (FOP) market share of the individual therapies, current and forecasted Fibrodysplasia Ossificans Progressiva (FOP) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Fibrodysplasia Ossificans Progressiva (FOP) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside the skeleton (extra-skeletal or heterotopic bone) that constrains movement. This process generally becomes noticeable in early childhood, starting with the neck and shoulders, and proceeding down the body and into the limbs.

Click Here- Free sample page

Epidemiology

The Fibrodysplasia Ossificans Progressiva (FOP) epidemiology division provide insights about historical and current Fibrodysplasia Ossificans Progressiva (FOP) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Report key facts-

1. Frederick et al. conducted a study in Philadelphia, United States, titled “Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis,” which stated that the worldwide prevalence of FOP is approximately 1 in 2,000,000. Phenotypic variability in the timing and intensity of flare-ups can be a diagnostic criterion for FOP without evidence of ethnic, racial, gender, or geographic predisposition.

2. According to the European Conference on Rare Diseases, FOP has a prevalence rate of 0.08 per 100,000 people.

3. As per the Delveinsight’sanalysis, the total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) in the seven major markets was found to be 630 in 2017. In the United States total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) was found to be 293 in 2017.

 Some of key major companies are working on this disease that are given below-

1. Ipsen Pharmaceuticals

2. Regeneron Pharmaceuticals

3. BioCryst Co.

Name of drugs covered which are given below-

1. Palovarotene

2. Garetosmab (REGN2477)

3. BLU-782

Table of content

1. Key Insights

2. Executive Summary of Fibrodysplasia Ossificans Progressiva (FOP)

3. Competitive Intelligence Analysis for Fibrodysplasia Ossificans Progressiva (FOP)

4. Fibrodysplasia Ossificans Progressiva (FOP) : Market Overview at a Glance

4.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Share (%) Distribution in 2017

4.2. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Share (%) Distribution in 2030

5. Fibrodysplasia Ossificans Progressiva (FOP) : Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Fibrodysplasia Ossificans Progressiva (FOP) Treatment and Management

8.2. Fibrodysplasia Ossificans Progressiva (FOP) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Fibrodysplasia Ossificans Progressiva (FOP) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

13. Fibrodysplasia Ossificans Progressiva (FOP) : Seven Major Market Analysis

13.1. Key Findings

13.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size in 7MM

13.3. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in the United States

15.1.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in Germany

15.3.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in France

15.4.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in Italy

15.5.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in Spain

15.6.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in the United Kingdom

15.7.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in Japan

15.8.3. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Fibrodysplasia Ossificans Progressiva (FOP)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Fibrodysplasia Ossificans Progressiva (FOP) market
  • To understand the future market competition in the Fibrodysplasia Ossificans Progressiva (FOP) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Fibrodysplasia Ossificans Progressiva (FOP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Fibrodysplasia Ossificans Progressiva (FOP) market
  • To understand the future market competition in the Fibrodysplasia Ossificans Progressiva (FOP) market

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Calendar

December 2020
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  

Categories